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Defying the Darkness:
Countering Cancer with Light
A Senior Thesis by Travis Hankins
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What’s the Focus?

•
•

▪

This research focused on treating Triple-Negative Breast Cancer (TNBC)
▪ TNBC tests negative for normal receptors in breast cancer
▪ Many current treatments rely on these receptors

▪

Design compound that can work without cell receptors

“Triple-Negative Breast Cancer.” Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 14 Sept. 2020, www.cdc.gov/cancer/breast/triple-negative.htm.
“Triple-Negative Breast Cancer.” YouTube, National Breast Cancer Foundation, Inc., 4 Sept. 2012, youtu.be/oAp4ZKbZU38.

What is Photodynamic Therapy?
▪

•
•
•

Photodynamic Therapy (PDT): treatment of cancer using light and a
photosensitive compound
▪ Advantages – less invasive, fewer side effects
▪ Disadvantages – relies on access to light, light sensitivity

“Photodynamic Therapy for Cancer.” National Cancer Institute, National Institutes of Health, 6 Sept. 2011, www.cancer.gov/about-cancer/treatment/types/surgery/photodynamic-fact-sheet.
“Getting Photodynamic Therapy.” Radiation Therapy, American Cancer Society, 2 Mar. 2020, www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/photodynamic-therapy.html.
Reynolds, Tom. “Photodynamic Therapy Expands Its Horizons.” JNCI: Journal of the National Cancer Institute, vol. 89, no. 2, 1997, pp. 112–114., doi:10.1093/jnci/89.2.112.

What are Porphyrins?

•

▪

Porphyrins: large, cyclic molecules
▪ Most widely known is heme,
a component in hemoglobin
▪ Chlorophyll – Mg-containing
porphyrin

▪

Highly versatile and stable due to
bond conjugation

▪

Research aimed to produce a novel
porphyrin that is a PDT agent

“Ch. 18: Porphyrins.” Journal of Chromatography Library, by Erich Heftmann, 5th ed., Elsevier, 1992, p. 337.

Structure of Porphin, one of
the simplest porphyrins

Project Goals
▪

Synthesize, purify, characterize, and test a novel porphyrin derivative

▪

To be a viable photodynamic agent:
▪ The porphyrin should be water soluble
▪ The porphyrin should be able to kill cells in low concentrations when
exposed to light
▪ The porphyrin should have a minimal effect on cells when not exposed to
light
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Synthesis of H2TPPC

pyrrole

4-formylbenzoic acid

H2TPPC

Synthesis of the Acid Chloride Porphyrin

H2TPPC

Acid Chloride Porphyrin

Synthesis of H2TPP-MorphMeOH

Acid Chloride Porphyrin

morpholin-2-yl methanol

H2TPP-MorphMeOH

1. Background
2. Synthesis
3. Purification and Characterization
4. Metabolic Analysis
5. Conclusions and Future Work

Product Purification
▪

•

The final product was purified
three ways: syringe filtration,
Sephadex LH-20, and Sephadex
G-50
▪ Syringe – eliminate coarse
particulate
▪ LH-20 – lipophilicity
▪ G-50 – molecular size

“Millex Syringe Filter, Nylon, Non-Sterile SLGN033.” Millipore Sigma, Sigma Aldrich, www.sigmaaldrich.com/catalog/product/mm/slgn033?lang=en&region=US

IR Spectroscopy

•

▪

Sample exposed to range of IR light,
monitor how much of each
wavelength is transmitted

▪

Certain bonds absorb certain
wavelengths and begin vibrating in
response → transmittance decreases

▪

Spectrum is used to identify
functionalities

Infrared (IR) Spectroscopy. 30 May 2020, https://chem.libretexts.org/@go/page/45256.

IR Spectroscopy

Amine

H2TPP-MorphMeOH

NMR Spectroscopy
▪

Sample hit with an
electromagnetic pulse,
causing the production
of signals

▪

Signals are interpreted
by the detector and
turned into a spectrum

▪

Spectrum is used to
elucidate structures

Amine

NMR Spectroscopy

H2TPP-MorphMeOH

UV-Vis Spectroscopy
H2TPP-MorphMeOH

Peaks
(nm)

Molar Absorptivity
Coefficient, ε (cm-1mM-1)

413
518
555
581
636

120
5.35
2.93
2.45
1.95

High-Performance Liquid Chromatography
▪

Purity is based on area of chromatogram that corresponds to the compound –
the purity of H2TPP-MorphMeOH was determined to be 98%
H2TPP-MorphMeOH
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MTT Analysis
▪

▪

▪

MTT analysis – method of
determining viability based on cell
metabolic activity.
Several concentrations of the
compound were tested across two
plates; one was kept in the dark,
and the other exposed to light.
Compound efficacy was
determined using LD50

Plate kept in the dark –
consistent, deep purple
color

Plate exposed to light –
color lessens as porphyrin
concentration increases and
cell death occurs

MTT Results for H2TPP-MorphMeOH
▪

Plated concentrations: 0, 1, 3, 10,
30 and 100 µM

▪

Plated concentrations: 0, 50, 100,
150, 200, and 250 µM
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Project Review
▪

The novel porphyrin H2TPP-MorphMeOH was successfully synthesized from
H2TPPC and the amine morpholin-2-yl methanol
▪ The product was successfully purified (HPLC)
▪ The product retained internal structure (UV-Vis, NMR)
▪ The product coupled with the amine (NMR, IR)

▪

H2TPP-MorphMeOH was determined to be a weak antineoplastic agent based
on the results of the MTT assays

Project Goals (Revisited)
▪

Synthesize, purify, characterize, and test a novel porphyrin derivative

▪

To be a viable photodynamic therapy agent:
▪ The porphyrin should be water soluble
▪ The porphyrin should be able to kill cells in low concentrations when
exposed to light
▪ The porphyrin should have minimal effect on cells when not exposed to
light

▪

Since H2TPP-MorphMeOH doesn’t satisfy all three requirements, it would not
be fit as a PDT agent

Future Work
▪

Re-perform second MTT assay to resolve error

▪

Continue exploring H2TPP-MorphMeOH’s potential uses

▪

Continue searching for and developing other porphyrin derivatives
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